advantages of continuous infusion are the long-term exposure of tumour cells to the drug and the fact that most toxic effects are reduced for doxorubicin , epirubicin and mitoxantrone due to elimination of the high peak plasma levels .
C0013089
doxorubicin
C0014582
epirubicin